Blood lipids are heritable, modifiable risk factors for coronary artery disease (CAD) 1,2 , a leading cause of death 3 . Human genetic studies of lipid levels can identify targets for new therapies for cholesterol management and the prevention of heart disease and can complement studies in model organisms 4,5 . Studies of naturally occurring genetic variation can proceed through large-scale association analyses focused on unrelated individuals or through the investigation of mendelian forms of dyslipidemia in families 6 . We previously identified 95 loci associated with blood lipids, accounting for ~10-12% of total trait variance 4 , and showed that variants with small effects can indicate pathways and therapeutic targets that enable clinically important changes in blood lipid levels 4,7 .
A r t i c l e s Levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides and total cholesterol are heritable, modifiable risk factors for coronary artery disease. To identify new loci and refine known loci influencing these lipids, we examined 188,577 individuals using genome-wide and custom genotyping arrays. We identify and annotate 157 loci associated with lipid levels at P < 5 × 10 −8 , including 62 loci not previously associated with lipid levels in humans. Using dense genotyping in individuals of European, East Asian, South Asian and African ancestry, we narrow association signals in 12 loci. We find that loci associated with blood lipid levels are often associated with cardiovascular and metabolic traits, including coronary artery disease, type 2 diabetes, blood pressure, waist-hip ratio and body mass index. Our results demonstrate the value of using genetic data from individuals of diverse ancestry and provide insights into the biological mechanisms regulating blood lipids to guide future genetic, biological and therapeutic research.
variants from the 1000 Genomes Project 9 and focused resequencing 10 efforts in 64 previously associated loci (28, 923 SNPs) and finemapping variants in 181 loci associated with other traits (93,308 SNPs). In cases where Metabochip and GWAS array data were available for the same individuals, we used Metabochip data to ensure that key variants were directly genotyped rather than imputed.
We excluded individuals known to be on lipid-lowering medications and evaluated the additive effect of each SNP on blood lipid levels after adjusting for age and sex. Genomic control values 11 for the initial meta-analyses were 1.10-1.15, low for a sample of this size, indicating that population stratification should have had only a minor impact on our results (Supplementary Fig. 2) . After genomic control correction, 157 loci associated with blood lipid levels were identified (P < 5 × 10 −8 ), including 62 newly associated loci ( Fig. 1,  Tables 1-4 and Supplementary Tables 2 and 3) . Loci were >1 Mb apart and nearly independent (r 2 < 0.10). Of the 62 newly associated loci, 24 demonstrated the strongest evidence of association with HDL cholesterol levels, 15 demonstrated the strongest evidence of association with LDL cholesterol levels, 8 demonstrated the strongest evidence of association with triglyceride levels, and 15 demonstrated the strongest evidence of association with total cholesterol (Supplementary Fig. 3) . Several of these loci were validated by a similar extension based on published Global Lipids Genetics Consortium GWAS results 12 .
The effects of newly identified loci were generally smaller than in earlier GWAS (Supplementary Fig. 4 ). For the 62 newly identified variants, trait variance explained in the Framingham offspring was 1.6% for HDL cholesterol levels, 2.1% for triglyceride levels, 2.4% for LDL cholesterol levels and 2.6% for total cholesterol levels.
Overlap of genetic discoveries and previous knowledge
To investigate connections between our new loci and known lipid biology, we first catalogued genes within 100 kb of the peak associated SNPs and searched PubMed and Online Mendelian Inheritance in Man (OMIM) A r t i c l e s for occurrences of these gene names and their aliases in the context of relevant keywords. After manual curation, we identified at least 1 strong candidate in 32 of the 62 loci (52%) ( Supplementary Table 4 ). For the remaining 30 loci, we found no literature support for the role of a nearby gene in regulating blood lipid levels. This search highlighted genes whose connections to lipid metabolism have been extensively documented in mouse models (such as VLDLR 13 and LRPAP1 (ref. 13) ) and human cell lines (such as VIM 14 ), as well as candidates whose connection to lipid levels is more recent, such as VEGFA. With respect to the latter, recent studies of VEGFB have suggested that vascular endothelial growth factors have an unexpected role in the targeting of lipids to peripheral tissues 15 , which we corroborate by associating variants near VEGFA with blood triglyceride and HDL cholesterol levels.
Multiple types of evidence supported several literature-identified candidates ( Supplementary Table 2 ). For example, VLDLR is categorized by Gene Ontology (GO) 16 in the retinoid X nuclear receptor (RXR) activation pathway, which also includes genes (APOB, APOE, CYP7A1, APOA1, HNF1A and HNF4A) in previously implicated loci 4 . However, because these additional sources of evidence build on overlapping knowledge, they are not truly independent.
To estimate the probability of finding ≥32 literature-supported candidates after automated search and manual review of results, we repeated our text-mining literature search using 100 permutations of SNPs matched for allele frequency, distance to the nearest gene and number of proxies in linkage disequilibrium (LD). To approximate manual curation of the text-mining results, we focused on genes implicated by 3 or more publications (25 in observed data, 8.7 on average in control SNP sets, P = 8 × 10 −8 ).
Pathway analyses
We performed a gene set enrichment analysis, using MAGENTA 17 to evaluate the over-representation of biological pathways among associated loci. Across the 157 loci, MAGENTA identified 71 enriched pathways. These pathways included at least 1 gene in 20 of our newly identified loci ( Supplementary Table 5 ). Examples included DAGLB (connected to previously associated loci by genes in the triglyceride lipase activity pathway), INSIG2 (connected to previously associated loci by the cholesterol and steroid metabolic process pathways), AKR1C4 (connected to previously associated loci by the steroid metabolic process and bile acid biosynthesis pathways), VLDLR (connected to previously associated loci by the retinoic X receptor activation and lipid transport pathways, among others) and PPARA, ABCB11 and UGT1A1 (three genes assigned to pathways implicated in the activation of nuclear hormone receptors, which have an important role in lipid metabolism through the transcriptional regulation of genes in sterol metabolic pathways 18 ). Of the 16 loci where literature review and pathway analysis both suggested a candidate, the predictions overlapped 14 times ( Supplementary Table 2 ; by chance, we expected 6.6 overlapping predictions; P = 1 × 10 −5 ).
Protein-protein interactions
We assessed evidence for physical interactions between proteins encoded near our associated SNPs using DAPPLE 19 . We found an excess of direct protein-protein interactions for genes in loci associated with LDL cholesterol levels (ten interactions; P = 0.0002), HDL cholesterol levels (eight interactions; P = 0.002) and total cholesterol levels (six interactions; P = 0.017) but not for triglyceride levels (two interactions; P = 0.27) ( Supplementary Fig. 5 ). Most of the interactions involved genes at known loci (such as the interaction network connecting PLTP, APOE, APOB and LIPC) or highlighted the same genes as the literature and pathway analyses (such as those connecting VLDLR, APOE, APOB, CETP and LPL). Among the new loci, we identified a link between AKT1 and GSK3B. GSK3B has been shown to have a role in energy metabolism 20 , and its activity is regulated by AKT1 through phosphorylation 21 . Literature review also supported a role in the regulation of blood lipid levels for these two genes.
Regulation of gene expression by associated variants
Many variants associated with complex traits act through the regulation of gene expression. We examined whether our 62 newly identified variants were associated with the expression levels of nearby genes in liver, omental fat or subcutaneous fat. Fifteen variants were associated with the transcript levels of a nearby gene at a significance of P < 5 × 10 −8 ( Supplementary Table 6 ), and seven lipid-associated variants were in strong LD (r 2 > 0.8) with the strongest expression quantitative trait locus (eQTL) for the region (r 2 > 0.8). In three of these loci, literature Figure 1 Overlap of loci associated with different lipid traits. The Venn diagram illustrates the number of loci that show association with multiple lipid traits. The number of loci primarily associated with only one trait is listed in parentheses after the trait name, and locus names are listed below. Loci that show association with two or more traits are shown in the appropriate segment. npg A r t i c l e s searches also prioritized candidate genes. In all three, eQTL analysis and literature review identified the same candidate (DAGLB, SPTLC3 and PXK; P = 0.05). For the remaining four loci (near RBM5, ADH5, TMEM176A and GPR146), analysis of expression levels identified candidates that were not supported by literature or pathway analyses.
Coding variation
In some loci where previous association studies of coding variants were inconclusive, we now found convincing evidence of association, demonstrating the benefits of the large sample sizes achievable through collaboration. For example, in the APOH locus 22 , our most strongly associated variant was rs1801689 (APOH p.Cys325Gly; P = 1 × 10 −11 for LDL cholesterol levels). Overall, at 15 of the 62 new loci, there was at least 1 nonsynonymous variant within 100 kb of and in strong LD (r 2 > 0.8) with the index SNP ( Supplementary Table 7 ) (18 loci when there was no restriction on distance). This ~30% overlap between associated loci and coding variation is similar to that for other complex traits 9 . Unexpectedly, in the 11 loci where a candidate Chr., chromosome; A1, minor allele; A2, major allele; TG, triglycerides; TC, total cholesterol. Effect sizes are given with respect to the minor allele (A1) in s.d. For loci associated with two or more traits at genome-wide significance, the trait corresponding to the strongest P value is listed first. a The secondary trait was most strongly associated with a different SNP: rs719726 (within 1 Mb of rs1936800, r 2 = 0.74). b The secondary trait was most strongly associated with a different SNP, rs9930333 (within 1 Mb of rs1121980, r 2 = 0.99). A r t i c l e s was suggested by literature review and by examination of coding variation, the candidates from these methods coincided 7 times (P = 0.03 compared to the expected overlap by chance of 3.8 times); thus, agreement between literature review and examination of coding variation was less significant than for eQTL studies and analyses of pathways or protein-protein interactions.
Overlap between association signals and regulators of transcription in liver
Despite our efforts, 18 of the 62 newly identified loci remain without prioritized candidate genes. The liver is an important hub of lipid biosynthesis, and there is evidence that lipid-associated variants might be associated with changes in gene regulation in liver cells 23 . Using Encyclopedia of DNA Elements (ENCODE) data 23 , we evaluated whether associated SNPs overlapped experimentally annotated functional elements identified in HepG2 cells, a commonly used model of human hepatocytes. To determine significance, we generated 100,000 lists of permuted SNPs, matched for minor allele frequency (MAF), distance to the nearest gene and number of SNPs in LD (r 2 > 0.8) (Online Methods). In HepG2 cells, lipid-associated SNPs were enriched in 8 of the 15 functional chromatin states defined by Ernst et al. 24 (P < 1 × 10 −5 ; Supplementary Table 8 ). The strongest enrichment was in regions with 'strong enhancer activity' (3.7-fold enrichment; P = 2 × 10 −25 ; Supplementary Table 9 ). In the other eight cell types examined by Ernst et al., no more than three functional chromatin states showed evidence for enrichment (and, when present, enrichment was weaker).
We proceeded to investigate the overlap between lipidassociated loci and functional marks in HepG2 cells in more detail ( Supplementary Table 9 ). Notable regulatory elements showing significant overlap with lipid-associated loci included histone marks associated with active regulatory regions (acetylation of histone H3 at lysine 27 (H3K27ac), P = 3 × 10 −20 ; acetylation of histone H3 at lysine 9 (H3K9ac), P = 3 × 10 −22 ), promoters (trimethylation of histone H3 at lysine 4 (H3K4me3), P = 2 × 10 −15 ; dimethylation of histone H3 at lysine 4 (H3K4me2), P = 8 × 10 −12 ), transcribed regions (trimethylation of histone H3 at lysine 36 (H3K36me3), P = 4 × 10 −14 ), indicators of open chromatin (FAIRE (formaldehyde-assisted isolation of regulatory elements), P = 5 × 10 −9 ; DNase I sensitivity, P = 2 × 10 −4 ) and regions that interact with the transcription factors HNF4A (P = 6 × 10 −10 ) and CEBP/B (P = 1 × 10 −5 ). Overall, 56 of our 62 new loci contained at least 1 SNP that overlapped a functional mark 24 and/or chromatin state 23 highlighted in Supplementary  Table 9 , including all but 3 of the loci where no candidates were suggested by literature review or analyses of pathways, coding variation or gene expression ( Supplementary Table 10 ).
Initial fine mapping of 65 lipid-associated loci
Previous fine mapping of five LDL cholesterol-associated loci found that variants with the strongest association were often substantially different in frequency and effect size from those identified by GWAS 10 . Metabochip genotypes enabled us to carry out an initial fine-mapping analysis for 65 loci: 60 selected for fine mapping on Chr., chromosome; A1, minor allele; A2, major allele; TG, triglycerides; TC, total cholesterol. Effect sizes are given with respect to the minor allele (A1) in s.d. For loci associated with two or more traits at genome-wide significance, the trait corresponding to the strongest P value is listed first.
a At one locus, secondary traits were most strongly associated with a different SNP, rs6818397 (within 1 Mb of rs6831256, r 2 = 0.18).
npg
A r t i c l e s the basis of our previous study 4 and 5 nominated for fine mapping because of association with other traits. For each of these loci, we identified the most strongly associated Metabochip variant and evaluated whether it (i) reached genomewide significant evidence for association (to avoid chance fluctuations in regions where the signal was relatively weak) and (ii) was different from the GWAS index SNP in terms of frequency and effect size (operationalized to r 2 < 0.8 with the GWAS index SNP). In the European samples, fine mapping identified eight loci where the fine-mapping signal was clearly different from the GWAS signal ( Supplementary  Table 11 ). The two largest differences were at the loci near PCSK9 We also attempted fine mapping in samples with African (n = 3,263), East Asian (n = 1,771) and South Asian (n = 4,901) ancestry. Despite comparatively small sample sizes, ancestry-specific analyses identified associated SNPs clearly distinct from the original GWAS variant in five loci ( Supplementary Table 11 ). These loci included APOE, consistent with the analyses in individuals of European ancestry, three loci where differences in LD between populations enabled fine mapping in samples of African (SORT1 and LDLR) or East Asian (APOA5) ancestry and CETP, where an African ancestry-specific variant was present. For CETP, SORT1 and APOA5, results are consistent with those of other fine-mapping and functional studies 7, 25, 26 .
Association of lipid-related loci with metabolic and cardiovascular traits
To evaluate the role of the 157 loci identified here in related traits, we evaluated the most strongly associated SNPs for each locus in genetic studies of CAD (n = 114,590, including 37,653 cases) 27,28 , type 2 diabetes (T2D; n = 47,117, including 8,130 cases) 29 , body mass index (BMI; n = 123,865 individuals) 30 and waist-hip ratio (WHR; n = 77,167 individuals) 31 , systolic and diastolic blood pressure (SBP and DBP; n = 69,395 individuals) 32 and fasting glucose levels (n = 46,186 non-diabetic individuals) 33 . We observed an excess of SNPs nominally associated (P < 0.05) with all these traits, including a 5.1-fold excess for CAD (40 nominally significant loci; P = 2 × 10 −19 ), a 4.1-fold excess for BMI (32 loci; P = 1 × 10 −11 ), a 3.7-fold excesses for DBP (29 loci; P = 1 × 10 −9 ), a 3.4-fold excess for WHR (27 loci; P = 1 × 10 −9 ), a 2.5-fold excess for SBP (20 loci; P = 1 × 10 −4 ), a 2.3-fold excess for T2D (18 loci; P = 0.001) and a 2.2-fold excess for fasting glucose levels (17 loci; P = 3 × 10 −3 ) ( Supplementary Table 12 ). Interestingly, for the new loci, we observed greater overlap with BMI, SBP and DBP (nine overlapping loci each) than with CAD (eight overlapping loci). Of the new loci, the two SNPs showing the strongest association with CAD mapped near RBM5 (rs2013208: P HDL = 9 × 10 −12 , P CAD = 7 × 10 −5 ) and CMTM6 (rs7640978: P LDL = 1 × 10 −8 , P CAD = 4 × 10 −4 ).
We tested whether the LDL cholesterol-, total cholesterol-or triglyceride-increasing allele or the HDL cholesterol-decreasing allele was associated with increased risk of cardiovascular disease or related metabolic outcomes; the direction of effect of each locus was categorized according to the primary association signal at the locus, as in Tables 1-4 . We observed association with increased CAD risk (104/149; P = 1 × 10 −6 ), SBP (96/155; P = 2.7 × 10 −3 ) and WHR adjusted for BMI (92/154; P = 0.019). There were many instances where a single locus was associated with many traits. These included variants near FTO, consistent with previous reports 34 ; near VEGFA (associated with triglyceride levels, CAD, T2D, SBP and DBP); near SLC39A8 (associated with HDL cholesterol levels, BMI, SBP and DBP); and near MIR581 (associated with HDL cholesterol levels, BMI, T2D and DBP). In some cases, such as FTO, a strong association with BMI or another phenotype generated weaker association signals for other metabolic traits 34 . In other cases, such as SORT1, a primary effect on lipid levels might mediate secondary association with other traits, such as CAD 7 .
Association of lipid traits with CAD
Epidemiological studies consistently show that high total cholesterol and LDL cholesterol levels are associated with increased risk of CAD, whereas high HDL cholesterol levels are associated with reduced risk of CAD 35 . In genetic studies, the connection between LDL cholesterol levels and CAD is clear, whereas the results for HDL cholesterol levels are more equivocal [36] [37] [38] . In our data, trait-increasing alleles at the loci showing the strongest association with LDL cholesterol levels (31 loci), triglyceride levels (30 loci) or total cholesterol levels (38 loci) were associated with increased risk of CAD (P = 2 × 10 −12 , 2 × 10 −16 and 0.006, respectively). Conversely, trait-decreasing alleles at loci showing the strongest association with HDL cholesterol levels (64 loci) were associated with increased CAD risk at P = 0.02. When we focused on loci uniquely associated with LDL cholesterol levels (12 loci where P > 0.05 for other lipids), triglyceride levels (6 loci) or HDL cholesterol levels (14 loci), only the association with LDL cholesterol remained significant (P = 0.03).
To better explore how associations with individual lipid levels were related to CAD risk, we used linear regression to test whether association with lipid levels could predict impact on CAD risk. In this analysis, the effect on CAD of 149 lipid-associated loci (CAD results were not available for 8 SNPs) was correlated with LDL cholesterol (Pearson's r = 0.74; P = 7 × 10 −6 ) and triglyceride (Pearson's r = 0.46; P = 0.02) effect sizes but not with HDL cholesterol effect sizes (Pearson's r = -9 × 10 −4 ; P = 0.99; Supplementary Fig. 6 ). Because most variants affect multiple lipid fractions (Fig. 1) , dissecting the relationship between lipid level and CAD effects requires multivariate analysis. In a companion manuscript in this issue, we use multivariate analysis and detailed examination of triglyceride-associated loci to show that increased LDL cholesterol and triglyceride levels but not HDL cholesterol levels appear to be causally related to CAD risk 39 .
Evidence for additional loci not yet reaching genome-wide significance
To evaluate evidence for loci not yet reaching genome-wide significance, we compared the directions of effect in GWAS and Metabochip analyses of non-overlapping samples outside the 157 genome-wide significant loci. For independent variants (r 2 < 0.1) with association P < 0.1 in the GWAS-only analysis, a significant excess was concordant in the direction of effect for HDL cholesterol levels (62.9% in 1,847 SNPs; P < 1 × 10 −16 ), LDL cholesterol levels (58.6% of 1,730 SNPs; P < 1 × 10 −16 ), triglyceride levels (59.1% of 1,783 SNPs; npg A r t i c l e s P < 1 × 10 −16 ) and total cholesterol levels (61.0% of 1,904 SNPs; P < 1 × 10 −16 ), suggesting that there are many additional loci to be discovered in future studies.
DISCUSSION
Molecular understanding of the genes and pathways that modify blood lipid levels in humans will facilitate the design of new therapies for cardiovascular and metabolic disease. This understanding can be gained from studies of model organisms, in vitro experiments, bioinformatic analyses and human genetic studies. Here we demonstrate association between blood lipid levels and 62 new loci, bringing the total number of lipid-associated loci to 157 (Tables 1-4 and Fig. 1 ). All but one of the loci identified here include protein-coding genes within 100 kb of the SNP showing the strongest association. Whereas 38 of the 62 new loci include genes whose role in the regulation of blood lipid levels is supported by literature review or analysis of curated pathway databases, the remainder include only genes whose role in such regulation has not been documented.
In total, there are 240 genes within 100 kb of 1 of our 62 new lipidassociated loci-providing a daunting challenge for future functional studies. Prioritizing on the basis of literature review, pathway analysis, regulation of mRNA expression levels and protein-altering variants suggests that 70 genes in 44 of the 62 new loci might be the focus of the first round of functional studies (summarized in Supplementary  Table 2 ). Although we found significant overlap, different sources of prioritization sometimes disagreed. This result suggests that truly understanding causality will be very challenging. We include an interpreted digest of genes highlighted by our study in the Supplementary Note. Clearly, a range of approaches will be needed to follow up these findings. To illustrate possibilities, consider US Patent Application 20090036394 disclosing that, in the mouse, knockout of Gpr146 modifies blood lipid levels. Here we show that variants near the human homolog of this gene, GPR146, are associated with the levels of total cholesterol-providing an added incentive for studies of GPR146 inhibitors in humans. GPR146 encodes a G protein-coupled receptor, an attractive pharmaceutical target, so it is tempting to speculate that, one day, pharmaceutical inhibition of GPR146 may modify cholesterol levels and reduce risk of heart disease.
Each associated locus typically includes many strongly associated (and potentially causal) variants. Our fine-mapping results illustrate how genetic analysis of large samples and individuals of diverse ancestry can help focus the search for causal variants. In our finemapping analysis of 65 lipid-associated loci, we were able to separate the strongest signal in a region from the previous GWAS-identified signal in 12 instances. In 3 of these 12 instances, fine mapping was enabled by the analysis of a few thousand individuals of African or East Asian ancestry, whereas, in the remaining instances, fine mapping was possible through the examination of nearly 100,000 individuals of European ancestry. A more detailed fine-mapping exercise, including imputation of variants from emerging, very large reference panels, may help refine the locations of additional signals.
Lipid-associated loci were strongly associated with CAD, T2D, BMI, SBP and DBP. In univariate analyses, we found that effects on LDL cholesterol and triglyceride levels all predicted association with CAD, but HDL cholesterol levels did not. In a companion paper, more detailed multivariate investigation shows that our data are consistent with the hypothesis that both LDL cholesterol and triglyceride levels but not HDL cholesterol levels are causally related to CAD risk. HDL cholesterol, LDL cholesterol and triglyceride levels summarize aggregate levels of different lipid particles, each with potentially distinct consequences for CAD risk. We evaluated the association of our loci with lipid subfractions in 2,900 individuals from the Framingham Heart Study (Supplementary Fig. 7 and Supplementary Table 13 ) and with sphingolipids, which are components of lipid membranes in cells, in 4,034 individuals from 5 samples of European ancestry 40 ( Supplementary Table 14 ). The results suggest that HDL cholesterol-associated variants can have a markedly different impact on these subphenotypes. For example, among HDL cholesterolassociated loci, variants near LIPC were strongly associated with plasmalogen levels (P < 1 × 10 −40 ), variants near ABCA1 were associated with sphingomyelin levels (P <1 × 10 −5 ), and variants near CETP, which show the strongest association with HDL cholesterol levels overall, were associated with neither of these. Detailed genetic dissection of these subphenotypes in larger samples could lead to functional groupings of HDL cholesterol-associated variants that reconcile the results of genetic studies (which show no clear connection between HDL cholesterol-associated variants and CAD risk) and epidemiological studies (which show clear association between plasma HDL cholesterol levels and CAD risk).
In summary, we report the largest genetic association study of blood lipid levels yet conducted. The large number of loci identified, the many candidate genes they contain and the diverse proteins they encode generate new leads and insights into lipid biology. It is our hope that the next round of genetic studies will build on these results, using new sequencing, genotyping and imputation technologies to examine rare loss-of-function alleles and other variants of clear functional impact to accelerate the translation of these leads into mechanistic insights and improved treatments for CAD.
URLs.
Summary results for our studies are available. We hope that they will facilitate continued research into the genetics of blood lipid levels and, eventually, help identify improved treatments for CAD. To browse the full result set, go to http://www.sph.umich. edu/csg/abecasis/public/lipids2013/. Snipper, http://csg.sph.umich. edu/boehnke/snipper/; DAPPLE, http://www.broadinstitute.org/ mpg/dapple/dapple.php.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Samples studied. We collected summary statistics for Metabochip SNPs from 45 studies. Of these, 37 studies consisted primarily of individuals of European ancestry (see Supplementary Table 1 and the Supplementary Note for details), including both population-based studies and case-control studies of CAD and T2D. Another 8 studies consisted primarily of individuals with non-European ancestry, including 2 studies of individuals of South Asian descent, AIDHS/SDS (n = 1,516) and PROMIS (n = 3,385); 2 studies of individuals of East Asian descent, CLHNS (n = 1,771) and TAI-CHI (n = 7,044); and 5 studies of individuals of recent African ancestry, MRC/UVRI GPC (n = 1,687) from Uganda, SEY (n = 426) from the Caribbean, and FBPP (n = 1,614; triglyceride results unavailable), GXE (n = 397) and SPT (n = 838) from the United States (more details in Supplementary Table 1 and the Supplementary Note) . Each contributing study individually obtained ethics approval for their data generation and analyses.
Genotyping. We genotyped 196,710 genetic variants prioritized on the basis of previous GWAS for cardiovascular and metabolic phenotypes using the Illumina iSelect Metabochip 8 genotyping array. To design the Metabochip, we used our previous GWAS of ~100,000 individuals 4 to prioritize 5,023 SNPs for HDL cholesterol, 5,055 SNPs for LDL cholesterol, 5,056 SNPs for triglycerides and 938 SNPs for total cholesterol. These independent SNPs represent most loci with P < 0.005 in our original GWAS for HDL cholesterol, LDL cholesterol and triglycerides and with P < 0.0005 for total cholesterol. An additional 28,923 SNPs were selected for fine mapping of 65 previously identified lipid loci. The Metabochip also included 50,459 SNPs prioritized on the basis of GWAS of non-lipid traits and 93,308 SNPs selected for fine mapping of loci associated with non-lipid traits (5 of these loci were associated with blood lipids by the analyses described here).
Phenotypes. Blood lipid levels were typically measured after >8 h of fasting. Individuals known to be on lipid-lowering medication were excluded when possible. LDL cholesterol levels were directly measured in ten studies (24% of total study individuals) and were estimated using the Friedewald formula 41 in the remaining studies. Trait residuals within each study cohort were adjusted for age, age 2 and sex and were then quantile normalized. Explicit adjustments for population structure using principal-component 42 or mixedmodel approaches 43 were carried out in 24 studies (35% of study individuals); all studies were adjusted using genomic control before meta-analysis 11 .
In studies ascertained on diabetes or cardiovascular disease status, cases and controls were analyzed separately (Supplementary Table 1 ). All meta-analyses were limited to a single ancestry group (for example, European only).
Primary statistical analysis.
Individual SNP association tests were performed using linear regression with the inverse normal transformed trait values as the dependent variable and the expected allele count for each individual as the independent variable. These analyses were performed using PLINK (26 samples; 53% of the total number of individuals), SNPTEST (4 samples; 20% of the total number of individuals), EMMAX (9 samples; 14% of the total number of individuals), Merlin (4 samples; 9% of the total number of individuals), GENABEL (1 sample; 3% of the total number of individuals) and MMAP (1 sample; 1% of the total number of individuals) ( Supplementary Table 1 ).
Meta-analysis.
Meta-analysis was performed using the Stouffer method 44, 45 with weights proportional to the square root of the sample size for each sample.
To correct for inflated test statistics due to potential population stratification, we first applied genomic control to each sample and then repeated the procedure with initial meta-analysis results. For GWAS samples, we used all available SNPs when estimating the median test statistic and inflation factor λ. For Metabochip samples, we used a subset of SNPs (n = 7,168) that had P values of >0.50 for all lipid traits in the original GWAS, expecting that the majority of these would not be associated with lipids and would behave as null variants in the Metabochip samples. Signals were considered to be novel if they reached a P value of <5 × 10 −8 in the combined GWAS and Metabochip meta-analysis and were >1 Mb away from the nearest previously described lipid-associated locus and other new loci. We used only European samples for the discovery of new genome-wide significant loci. Non-European samples were used only for meta-analysis and examination of fine-mapping analyses.
Quality control. To flag potentially erroneous analyses, we carried out a series of quality control steps. Average standard errors for association statistics from each study were plotted against study sample size to identify outlier studies. We inspected allele frequencies to ensure all analyses used the same strand assignment of alleles. We evaluated whether reported statistics and allelic effects were consistent with published findings for known loci. Genomic control values for study-specific analyses were inspected, and all were <1.20. Finally, within each study, we excluded variants for which the minor allele was observed <7 times.
Proportion of trait variance explained. We estimated the increase in trait variance explained by new loci in the Framingham cohort (n = 7,132) using 3 models for each trait residual: (i) lead and secondary SNPs from the previously published loci 4 ; (ii) previously published lipid loci plus newly reported loci; and (iii) newly reported loci. We regressed lipid residuals on these sets of SNPs using the lme kinship package in R.
Initial automated review of the published literature. An initial list of candidates within each locus was generated with Snipper and then subjected to manual review. For each locus, Snipper first generates a list of nearby genes and then checks for the co-occurrence of the corresponding gene names and selected search terms ("cholesterol", "lipids", "HDL", "LDL" or "triglycerides") in published literature and OMIM. We supplemented this approach with traditional literature searches using PubMed and Google.
Generating permuted sets of non-associated SNPs. To estimate the expected chance overlap between literature searches and our loci, we generated lists of permuted SNPs. To generate these lists, we first identified all non-associated lipid-related SNPs (P > 0.10 for any of the four lipid traits) and created bins on the basis of three statistics: MAF, distance to the nearest gene and number of SNPs with r 2 > 0.8. For each index SNP, we identified 500 non-lipidassociated SNPs that fell within the same 3 bins and randomly selected 1 SNP for each permuted list.
Pathway analyses. To investigate whether lipid-associated variants overlapped previously annotated pathways, we used gene set enrichment analysis (GSEA), as implemented in MAGENTA 17 using the meta-analysis of all studies, including GWAS and Metabochip SNPs. Briefly, MAGENTA first assigns SNPs to a given gene when within 110 kb upstream or 40 kb downstream of transcript boundaries. The most significant SNP P value within this interval is then adjusted for confounders (gene size, marker density and LD) to create a gene association score. When the same SNP is assigned to multiple genes, only the gene with the lowest score is kept for downstream analyses. Subsequently, MAGENTA attaches pathway terms to each gene using several annotation resources, including GO, PANTHER, Ingenuity and KEGG. Finally, the genes are ranked on the basis of their gene association scores, and a modified GSEA test is used to test the null hypothesis that all gene score ranks above a given rank cutoff are randomly distributed with regard to a given pathway term (and compared to multiple randomly sampled gene sets of identical size). We evaluated enrichment using a rank cutoff of 5% of the total number of genes. A minimum of 10,000 gene set permutations were performed, and up to 1,000,000 permutations were performed for GSEA P values below 1 × 10 −4 . We used the Disease Association Protein-Protein Link Evaluator package (DAPPLE) to examine evidence for protein-protein interaction networks connecting genes across different lipid-related loci. This analysis included the 62 new loci as well as the 95 previously known loci; we focus our discussion on pathways that included 1 or more genes from new loci.
Cis-expression quantitative trait locus analysis.
To determine whether lipidassociated SNPs might act as cis regulators of nearby genes, we examined association with the expression levels of 39,280 transcripts in 960 human liver samples, 741 human omental fat samples and 609 human subcutaneous fat samples. Tissue samples were collected postmortem or during surgical resection from donors; tissue collection, DNA and RNA isolation, expression profiling and genotyping were performed as described 46 . MACH was used to obtain imputed genotypes for ~2.6 million SNPs in HapMap release 22 for each of the samples. We examined the correlation between each of the 62 new npg
